Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Acinetobacter
28%
Active Pharmaceutical Ingredients
14%
Activity Rate
14%
Antimicrobial
28%
Broad Spectrum Antimicrobial Agent
14%
Carbapenem
42%
Ceftazidime
28%
Ciprofloxacin
28%
Citrobacter
14%
Clinical Laboratory
28%
Emerging Resistance
14%
Enterobacter
14%
Enterobacteriaceae
14%
Epidemic Spreading
14%
Escherichia Coli
14%
Imipenem
14%
In Vitro Activity
14%
Information Collection
100%
International Surveillance
14%
Klebsiella
14%
Laboratory Standards
28%
Medical Center
100%
Meropenem
100%
MIC Method
14%
MIC90
14%
Molecular Methods
14%
Molecular Typing
14%
National Committee
28%
Oxacillin-susceptible
14%
Piperacillin-tazobactam
14%
Program Results
14%
Proteus Mirabilis
14%
Pseudomonas Aeruginosa (P. aeruginosa)
14%
Reducing Activity
14%
Resistance Risk
14%
Resistant Strains
14%
Serratia
14%
Spectrum of Activity
14%
Staphylococcus
28%
Surveillance Network
14%
Susceptibility Methods
14%
Susceptibility Rate
28%
Susceptibility Testing
100%
Test Information
100%
Tobramycin
14%
United States
100%
Pharmacology, Toxicology and Pharmaceutical Science
Acinetobacter
28%
Antiinfective Agent
42%
Carbapenem
28%
Carbapenem Derivative
14%
Ceftazidime
28%
Ciprofloxacin
28%
Citrobacter
14%
Enterobacter
14%
Enterobacteriaceae
14%
Escherichia coli
14%
Imipenem
14%
Klebsiella
14%
Meropenem
100%
Oxacillin
14%
Piperacillin Plus Tazobactam
14%
Proteus mirabilis
14%
Pseudomonas aeruginosa
14%
Serratia
14%
Staphylococcus
28%
Tobramycin
14%
Immunology and Microbiology
Acinetobacter
33%
Citrobacter
16%
Enterobacter
16%
Enterobacteriaceae
16%
Escherichia coli
16%
In Vitro
16%
Klebsiella
16%
MIC90
16%
Minimum Inhibitory Concentration
33%
Molecular Typing
16%
Proteus mirabilis
16%
Pseudomonas aeruginosa
16%
Resistant Strain
16%
Serratia
16%
Staphylococcus
33%
Susceptibility
100%